The Cardiac Procedure Surge
Across 1 sector, 2 filers are signaling rising demand. Visible since 2024Q1, recently quiet. Almost entirely a demand story (88%). One disclosure notes "18.4 percent increase in sales...primarily reflects higher procedure volumes in the U.S., the Asia Pacific region and various European countries."
Abbott is experiencing broad-based double-digit sales growth across electrophysiology, neuromodulation, vascular, and structural heart devices, driven by higher procedure volumes and product demand across U.S., Europe, and Asia Pacific markets.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Signals are all backward-looking performance reports with no shift in tone or risk posture across periods.
REPRESENTATIVE SIGNAL FROM FILINGS
“18.4 percent increase in sales...primarily reflects higher procedure volumes in the U.S., the Asia Pacific region and various European countries”
Electrophysiology sales increased 18.4% excluding foreign exchange effects, driven by higher procedure volumes across U.S., Asia Pacific, and Europe.
“Electrophysiology sales growth was driven by procedure growth, commercial execution, new product performance”
Electrophysiology sales increased due to procedure growth, commercial execution, and new product performance across VARIPULSE, TRUPULSE, NUVISION and CRYSTAL.
DRIVERS